Tumor-like amyloidosis of the upper respiratory tract

Быкова, В. П.; Daikhes, N. A.; Platonova, G. A.; Bakhtin, Alexander; Kornienko, K. A.; Romanenko, S. G.; Нажмудинов, И. И.

doi:10.17116/patol20198105174

Cited by 2 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Laryngeal local diseases such as laryngitis, squamous cancer of the larynx, and laryngeal abnormalities need topical drug administration 1 , 2 , 3 , 4 . As a result of multiple connective tissue barriers in the larynx, a number of studies have focused on the targeting or sustained release system to reduce frequency of multiple dosing and adverse effects.…”

Section: Introductionmentioning

confidence: 99%

Glycoside scutellarin enhanced CD-MOF anchoring for laryngeal delivery

Zhao

Guo

Wang

et al. 2020

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

It is essential to develop new carriers for laryngeal drug delivery in light of the lack of therapy in laryngeal related diseases. When the inhalable micron-sized crystals of γ -cyclodextrin metal-organic framework (CD-MOF) was utilized as dry powder inhalers (DPIs) carrier with high fine particle fraction (FPF), it was found in this research that the encapsulation of a glycoside compound, namely, scutellarin (SCU) in CD-MOF could significantly enhance its laryngeal deposition. Firstly, SCU loading into CD-MOF was optimized by incubation. Then, a series of characterizations were carried out to elucidate the mechanisms of drug loading. Finally, the laryngeal deposition rate of CD-MOF was 57.72 ± 2.19% improved by SCU, about two times higher than that of CD-MOF, when it was determined by Next Generation Impactor (NGI) at 65 L/min. As a proof of concept, pharyngolaryngitis therapeutic agent dexamethasone (DEX) had improved laryngeal deposition after being co-encapsulated with SCU in CD-MOF. The molecular simulation demonstrated the configuration of SCU in CD-MOF and its contribution to the free energy of the SCU@CD-MOF, which defined the enhanced laryngeal anchoring. In conclusion, the glycosides-like SCU could effectively enhance the anchoring of CD-MOF particles to the larynx to facilitate the treatment of laryngeal diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

Glycoside scutellarin enhanced CD-MOF anchoring for laryngeal delivery

Zhao

Guo

Wang

et al. 2020

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

show abstract

Plasma Cell Tumors in Hematological Classifications of 2022: WHO-HAEM5 (WHO, 5th edition) and ICC (International Consensus Classification). A Clinician’s View

Семочкин

2024

Clinical Oncohematology

View full text Add to dashboard Cite

In 2022, the hematological community was faced with a rather non-trivial event of simultaneous publication of two competitive classifications of hematopoietic and lymphoid tumors drawn up by different teams of the international leading experts. During the last 20 years, the generally recognized standard used for diagnosis was provided by several consecutive editions of classifications of hematological neoplasms published by the World Health Organization (WHO) in 2001, 2008, and 2016. Since the 4th edition of the WHO classification (WHO-HAEM4), new clinicopathologic, biological, and molecular knowledge has accumulated in this area, which promoted the refinement of diagnostic criteria for some diseases, the emergence of new terms, and the endorsement of notions previously defined as requiring further clarification. As a result, the next 5th edition of the WHO classification of tumours of haematopoietic and lymphoid tissues (WHO-HAEM5) was prepared and published as a preliminary article in the Leukemia. In this regard, it is worth noting that the final version of the WHO Blue Book was not released in 2023 and, therefore, can still be accomplished by some additions. Furthermore, in the same year of 2022, the Blood published the article “The International Consensus Classification of Mature Lymphoid Neoplasms” abbreviated to ICC. The authors of the two classifications hardly overlap. The present review compares these classifications with regard to new diagnostic criteria and verification of concrete clinicopathologic categories. The review largely focuses on plasma cell tumors and related B-cell lymphoproliferative diseases characterized by monoclonal immunoglobulin secretion.

show abstract

Tumor-like amyloidosis of the upper respiratory tract

Cited by 2 publications

References 3 publications

Glycoside scutellarin enhanced CD-MOF anchoring for laryngeal delivery

Glycoside scutellarin enhanced CD-MOF anchoring for laryngeal delivery

Plasma Cell Tumors in Hematological Classifications of 2022: WHO-HAEM5 (WHO, 5th edition) and ICC (International Consensus Classification). A Clinician’s View

Contact Info

Product

Resources

About